All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease

Acta Diabetol. 2021 Oct;58(10):1425-1428. doi: 10.1007/s00592-021-01746-2. Epub 2021 May 29.

Abstract

Aims: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden.

Methods: We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up.

Results: ENFORCE's survival C-statistic was 0.81 (95%CI: 0.72-0.89) and 0.78 (95%CI: 0.68-0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes.

Conclusions: In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients.

Keywords: Early stage; Mortality; Prediction model; Type 2 diabetes.

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Humans
  • Risk Factors